Structure Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
GPCR$21.73+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | | | | | |
| · · · YEAR ENDED DECEMBER 31, | ||||||
| · · 2024 · 2023 | ||||||
| Operating expenses: · · · · | ||||||
| Research and development | | $108,814 | | $70,103 | ||
| General and administrative | | 49,414 | | 32,672 | ||
| Total operating expenses | | 158,228 | | 102,775 | ||
| Loss from operations | | (158,228) | | (102,775) | ||
| Interest and other income, net | | 36,012 | | 13,391 | ||
| Loss before provision for income taxes | | (122,216) | | (89,384) | ||
| Provision for income taxes | | 310 | | 236 | ||
| Net loss attributable to ordinary shareholders | | $(122,526) | | $(89,620) | ||
| Net loss per share attributable to ordinary shareholders, basic and diluted | | $(0.78) | | $(0.81) | ||
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted | | 157,922 | | 110,198 | ||
| Other comprehensive gain: | | | ||||
| Unrealized gain on investments, net | | 393 | | 631 | ||
| Total other comprehensive gain | | 393 | | 631 | ||
| Comprehensive loss | | $(122,133) | | $(88,989) | ||
| | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.